Vaxart, Inc.
Enterprise to give a detailed overview of its norovirus clinical system
Webcast to be held on March 28, 2023 at 1:00 p.m. ET
SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT) currently announced it will host a crucial opinion leader video webcast on the well being and financial effect and illness burden for norovirus on Tuesday, March 28, 2023 at 1:00 p.m. ET.
The webcast will function presentations by prominent norovirus illness professionals Jan Vinjé, Ph.D., Head, National Calicivirus Laboratory, Centers for Illness Manage & Prevention, and Sarah Bartsch, Project Director, Public Wellness Informatics, Computational, and Operations Investigation, Investigation Foundation of the City University of New York.
In addition, Vaxart management will give a detailed overview of the Company’s investigational norovirus oral pill vaccine system, which includes its two existing Phase two clinical trials:
-
An ongoing Phase two GI.1 norovirus challenge study measuring the efficacy and security of our norovirus vaccine candidate. The study is also created to recognize a correlate of protection among immune responses to the vaccine and a reduction in danger of norovirus infection and / or extreme gastroenteritis. The Enterprise expects to report topline information from this study in Q3 2023.
-
A Phase two dose-ranging study of Vaxart’s bivalent norovirus oral vaccine candidate is created to recognize a vaccine dose for a prospective Phase three clinical trial. The Enterprise expects to report topline information from this study in mid-2023.
To register for the webcast, please click right here. A replay of the webcast will be accessible on the Company’s web page at www.vaxart.com following the conclusion of the occasion.
About the KOLs
Jan Vinjé, Ph.D.
Dr. Vinjé is head of the National Calicivirus Laboratory and Director of CaliciNet at the Centers for Illness Manage and Prevention (CDC) in Atlanta, GA. Dr. Vinjé received his Ph.D. degree at the University of Utrecht, the Netherlands, in 1999. Just after getting a postdoctoral fellowship and an appointment as investigation assistant professor at the University of North Carolina in Chapel Hill, he joined CDC in 2006. More than the previous ten years, he has served on various system advisory committees from various European investigation projects (FP6, FP7). He is serving as technical specialist on the norovirus subcommittee of the National Advisory Committee on Microbiological Criteria for Foods and is a member of the International Committee on Taxonomy of Viruses study groups on Caliciviridae (chair as of 2014) and Astroviridae. He is at present a member of the editorial board of the Journal of Clinical Microbiology and associate editor of the journal Meals and Environmental Virology, and he serves as an ad hoc reviewer for many higher-effect journals. Dr. Vinjé has published more than one hundred peer-reviewed publications and various book chapters. His investigation interests include things like all elements of viral gastrointestinal illness, which includes detection, characterization, and prevention and manage of norovirus infections.
Story continues
Sarah M. Bartsch, MPH
Ms. Bartsch is a Project Director and Senior Analyst with Public Wellness Informatics, Computational, and Operations Investigation (PHICOR), the Artificial Intelligence, Modeling, and Informatics for Nutrition Guidance and Systems (AIMINGS) Center, and the Center for Sophisticated Technologies and Communication in Wellness (CATCH), headquartered at the City University of New York (CUNY) Graduate College of Public Wellness and Wellness Policy. She has been a aspect of the group given that August of 2009 and has more than a decade of knowledge making use of systems approaches and establishing mathematical and computational models to help a wide variety of choice makers in public well being. Bartsch has authored more than 95 scientific publications, which includes additional than 30 as very first author.
About Vaxart
Vaxart is a clinical-stage biotechnology organization establishing a variety of oral recombinant vaccines primarily based on its proprietary delivery platform. Vaxart vaccines are created to be administered making use of tablets that can be stored and shipped with out refrigeration and do away with the danger of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is appropriate to provide recombinant vaccines, positioning the organization to create oral versions of at present marketed vaccines and to style recombinant vaccines for new indications. Vaxart’s improvement applications at present include things like pill vaccines created to defend against norovirus, coronavirus, seasonal influenza, and respiratory syncytial virus (RSV), as properly as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s very first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technologies and creations for oral vaccination making use of adenovirus and TLR3 agonists.
Note With regards to Forward-Hunting Statements
This press release includes forward-seeking statements that involve substantial dangers and uncertainties. All statements, other than statements of historical information, integrated in this press release with regards to Vaxart’s tactic, prospects, plans and objectives, outcomes from preclinical and clinical trials, commercialization agreements and licenses, and beliefs and expectations of management are forward-seeking statements. These forward-seeking statements may well be accompanied by such words as “must,” “think,” “could,” “prospective,” “will,” “anticipated,” “anticipate,” “strategy,” and other words and terms of comparable which means. Examples of such statements include things like, but are not restricted to, statements relating to Vaxart’s capacity to create and commercialize its item candidates, which includes its vaccine booster goods Vaxart’s expectations with regards to clinical outcomes and trial information and Vaxart’s expectations with respect to the effectiveness of its item candidates. Vaxart may well not truly obtain the plans, carry out the intentions, or meet the expectations or projections disclosed in the forward-seeking statements, and you must not location undue reliance on these forward-seeking statements. Actual outcomes or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-seeking statements. Different critical components could result in actual outcomes or events to differ materially from the forward-seeking statements that Vaxart tends to make.
Please also refer to the dangers described in the “Threat Components” sections of Vaxart’s Quarterly and Annual Reports filed with the SEC. Vaxart does not assume any obligation to update any forward-seeking statements, except as needed by law.
Contacts
Investor Relations:
Andrew Blazier
FINN Partners
IR@vaxart.com
(646) 871-8486
